Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A simple and convenient method for producing anti-activated lymphocyte alloantisera which does not require prior

R S Kerbel, R R Twiddy

    Journal of Immunological Methods
    |January 1, 1978
    PubMed
    Summary

    A B cell lymphoma, 2PK-3, was identified as activation lymphocyte alloantigen (Ala-1)-positive. This lymphoma provides a convenient source for generating anti-Ala-1 alloantisera for research applications.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Are there Fc receptors on non-lymphoreticular tumor cells?

    Immunology today·2014
    Same author

    NGR-TNF, a novel vascular-targeting agent, does not induce cytokine recruitment of proangiogenic bone marrow-derived cells.

    British journal of cancer·2013
    Same author

    Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib.

    British journal of cancer·2008
    Same author

    A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients.

    British journal of cancer·2008
    Same author

    Basic fibroblast growth factor and the complexity of tumour angiogenesis.

    Expert opinion on investigational drugs·2005
    Same author

    Cyclophosphamide-methotrexate 'metronomic' chemotherapy for the palliative treatment of metastatic breast cancer. A comparative pharmacoeconomic evaluation.

    Annals of oncology : official journal of the European Society for Medical Oncology·2005

    Area of Science:

    • Immunology
    • Oncology
    • Cell Biology

    Background:

    • Activation lymphocyte alloantigen (Ala-1) is a marker on activated lymphocytes.
    • Identifying reliable sources for generating specific alloantisera is crucial for immunological research.

    Purpose of the Study:

    • To determine if the Ala-1 phenotype is retained on neoplastic lymphocytes.
    • To evaluate the utility of a B cell lymphoma (2PK-3) as a source for generating anti-Ala-1 alloantisera.

    Main Methods:

    • Characterization of the 2PK-3 B cell lymphoma for Ala-1 expression using antibody absorption assays.
    • Immunization of DBA/2 mice with 2PK-3 cells to generate antisera.
    • Testing the generated antisera against normal and activated lymphocytes from various mouse strains.

    Related Experiment Videos

    Main Results:

    • The 2PK-3 lymphoma was confirmed to be Ala-1-positive.
    • Antisera generated from 2PK-3 cells specifically targeted activated lymphocytes from Ala-1.1 positive strains.
    • The antisera showed no significant cytotoxicity against normal spleen cells or activated lymphocytes from Ala-1.2 strains.

    Conclusions:

    • The Ala-1 phenotype can be retained on neoplastic lymphocytes.
    • 2PK-3 lymphoma cells are a practical and abundant source of immunogen for producing specific anti-Ala-1.1 alloantisera.
    • This finding facilitates the production of essential reagents for immunological studies.